EPICS CONGRESS COVERAGE: ASCO GI 2022 Highlights

Expert perspectives and strategic insights on the latest therapeutic developments in GI cancer treatment from the ASCO GI 2022 congress, and implications on individualized clinical decision-making.

January 26, 2022
Purchase Report

Faculty Chair

John Marshall, MD

Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA

Faculty Members

Tanios S. Bekaii-Saab, MD
Mayo Clinic, Phoenix, AZ, USA

Efrat Dotan, MD
Fox Chase Cancer Center, Philadelphia, PA, USA

David Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Julien Taieb, MD, PhD
Université Paris Descartes, Paris, France

Gerald Prager, MD, PhD
Medical University of Vienna, Austria

Dirk Arnold, MD, PhD
Asklepios Tumorzentrum Hamburg, Germany

Daniele Santini MD, PhD
University Campus Bio-Medico Rome, Italy

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

A report will be produced that is based on the meeting, and will discuss the following topics

  • Metastatic Colorectal Cancer – Targeted Therapy  
  • Metastatic Colorectal Cancer – Immunotherapy 
  • Hepatocellular Carcinoma
  • Gastric and Gastroesophageal Junction (GEJ) Cancers 
  • Pancreatic Cancer and Biliary Tract Cancer  

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.